Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment (Scientific Reports (2016) 6 (33825) DOI: 10.1038/srep33825);A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Du, F ^a,b   Yuan, P ^a   Zhao, Z T ^c   Yang, Z ^c   Wang, T ^c   Zhao, J D ^a   Luo, Y ^a   Ma, F ^a   Wang, J Y ^a   Fan, Y ^a   Cai, R G ^a   Zhang, P ^a   Li, Q ^a   Song, Y M ^c   Xu, B H ^a  

^a Hospital of Cancer   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MICRORNA; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; TIME FACTOR; TUMOR RECURRENCE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; ROC CURVE; TIME FACTORS; TRASTUZUMAB;

EID: 84988888007     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35509     Document Type: Erratum

References (26)

1. Siegel, R. L., Miller, K. D., & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7-30 (2016).
2. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
3. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869-10874 (2001).
4. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423 (2003).
5. Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2011).
6. Gianni, L. et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12, 236-244 (2011).
7. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
8. Lee, H. J. et al. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res. Treat. 145, 615-623 (2014).
9. Lee, H. J. et al. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am. J. Clin. Pathol. 144, 278-288 (2015).
10. Lee, H. J. et al. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. Am. J. Clin. Pathol. 144, 570-578 (2015).
11. Muendlein, A. et al. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. Eur. J. Cancer 50, 2134-2141 (2014).
12. Esquela-Kerscher, A., & Slack, F. J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).
13. Gong, C. et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 286, 19127-19137 (2011).
14. Jung, E. J. et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118, 2603-2614 (2012).
15. Huynh, F. C., & Jones, F. E. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance. PLoS ONE 9, e114419 (2014).
16. Bai, W. D. et al. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int. J. Cancer 135, 1356-1368 (2014).
17. Ye, X. et al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 47, 268-273 (2014).
18. Hanniford, D. et al. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. Clin. Cancer Res. 21, 4903-4912 (2015).
19. Kleivi, S. K. et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin. Cancer Res. 21, 1207-1214 (2015).
20. Zhang, J. X. et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. 14, 1295-1306 (2013).
21. Chan A. et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2016).
22. Wang, S. et al. Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma. Oncol. Rep. 33, 819-825 (2015).
23. Yin, Q. W., Sun, X. F., Yang, G. T., Li, X. B., Wu, M. S., & Zhao, J. Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol 8, 842-846 (2015).
24. Persson, H. et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res. 71, 78-86 (2011).
25. Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cutpoint optimization. Clin. Cancer Res. 10, 7252-7259 (2004).
26. Heagerty, P. J., Lumley, T., & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337-344 (2000).